The Intensively Follow-Up Examinations for Asymptomatic MPS I Infants in Taiwan
study id #: NCT04958070
condition: MPS I
status: Not yet recruiting
purpose:MPS I newborn screening has been executed in Taiwan nationwide since August 2015. Infants who failed the recheck at recall were referred to MacKay Memorial Hospital for a detailed confirmatory diagnosis. Urinary first-line biochemistry examinations including urinary GAG quantification (DMB/Cre. ratio), two-dimensional electrophoresis (2-D EP), and tandem mass spectrometry assay for predominant disaccharides derived from GAGs (i.e. CS, DS, HS, and KS) were performed. If the results were positive, a confirmative diagnosis was made according to the results of leukocyte enzymatic assay and molecular DNA analysis. Up to January 31, 2019, a total of 390,793 infants had been analyzed for MPS I, in those 11 suspicious cases were referred to MacKay Memorial Hospital for confirmation. The recall rates of MPS I was 0.0028%. Four of the 11 infants were confirmed to have MPS I. The prevalence rates of MPS I was 1.02 per 100,000 live births, respectively. Infants suspected of having MPS with a positive laboratory diagnosis but without any typical, clinical manifestations are not conformed to receive ERT under the treatment guideline of ERT for MPS in Taiwan. Distinctly, the clinical manifestations of MPS are irreversible and would be worse progressively while the symptoms have shown up. Receiving ERT at this time would effectively prevent the progression of illness, but, cannot rescue or reform the irreversible physical problems. By proceeding and undergoing an intensively long-term regular physical and laboratory examinations for asymptomatic infants with MPS I can effectively control the possibility of giving an ERT in a timely fashion.
intervention: MPS I
results: https://clinicaltrials.gov/ct2/show/results/NCT04958070
last updated: February 26, 2022
-
Real-World Data Assessment of Safety of Home-Based and Hospital/Outpatient-Based laronidase Enzyme Replacement Thera...Enzyme replacement therapy (ERT) is avai...
-
Issues of COVID-19-Related Distance Learning for Children With Neuronopathic MucopolysaccharidosesThe COVID-19 pandemic has impacted the e...
-
Deep Intronic Variant in the ARSB Gene as the Genetic Cause for Maroteaux-Lamy Syndrome (MPS VI)Maroteaux-Lamy syndrome (MPS-VI) is a ra...
-
Functional Assessment of the Genetic Findings Indicating Mucopolysaccharidosis Type II in the Prenatal SettingMucopolysaccharidosis type II (MPS II) i...
-
Extraordinary Experiences ProgramProgram provides grants of up to $1000 t...
-
Long-Term Safety and Clinical Outcomes of Intrathecal Heparan-N-Sulfatase in Patients With Sanfilippo Syndrome Type ...Currently, there is no effective therapy...
-
Corneal Cloudiness: A Presenting Feature of Mucopolysaccharidosis Type IA 10-y-old ‘short-statured’ male pre...